Loading...
Rani Therapeutics Holdings Community
NasdaqGM:RANI Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
Community Investing Ideas
Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Key Takeaways RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue. Extensive patent portfolio and cost containment measures enhance protection, licensing opportunities, and improve net margins.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$9
75.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
171.47% p.a.
Profit Margin
22.05%
Future PE
120.04x
Share price in 2028
US$6.04
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$9
75.6% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
287.72% p.a.
Profit Margin
23.22%
Future PE
59.37x
Share price in 2028
US$9.16